Terri B. Sebree - 18 Jul 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role
President
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Jul 2022
Net transactions value
-$9,109
Form type
4
Filing time
20 Jul 2022, 16:08:25 UTC
Previous filing
28 Jan 2022
Next filing
25 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award +30,000 +8.7% 376,146 18 Jul 2022 Direct F1
transaction ZYNE Common Stock Sale $9,109 -8,281 -2.2% $1.10 367,865 19 Jul 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 30,000 performance-based restricted stock awards granted in a prior year.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.